Andrew Slimmon, Morgan Stanley Investment Management senior portfolio manager, joins 'Squawk Box' to discuss the latest ...
Fintel reports that on December 9, 2024, Morgan Stanley downgraded their outlook for Lazard (NYSE:LAZ) from Overweight to ...
In a report released today, Betsy Graseck from Morgan Stanley maintained a Buy rating on Goldman Sachs Group (GS – Research Report), with a ...
Perhaps better late than never, Morgan Stanley has jumped on board the U.S. train — moving its rating on U.S. stocks to overweight, and targeting 6,500 at the end of 2025, compared to a June ...
Morgan Stanley says it's bullish on medtech in 2025 and upgraded Intuitive Surgical (ISRG), Tandem (TNDM), Stryker (SYK), ...
Morgan Stanley analyst Ryan Kenny upgraded Moelis (MC) to Overweight from Underweight with a price target of $92, up from $66. After this ...
The S&P 500 has delivered a median return of +1.5% during this month over the past 45 years, with positive results occurring ...
Morgan Stanley's Mike Wilson is now bullish on the stock market, setting a 2025 S&P 500 target of 6,500. He cites Fed rate cuts and potential deregulation, and says high-quality cyclical stocks ...
Global shares turned lower on Monday as traders focused on U.S. inflation data and chip stocks fell, while Beijing's promise ...
In this piece, we will take a look at Morgan Stanley’s top cyclical stocks for an economic recovery. As 2024 approaches its end, the stock market has been through it all. The driving theme of ...
It’s extremely difficult to predict short-term moves in the market with any accuracy. But the research, analysis, and ...